Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11635334 | 0.76 | KMT2A (0.51) | KMT2AMEN1MAPK1ALDH1A1LMNA | |
| SCHEMBL4252918 | 0.75 | KMT2A (1.00) | KMT2AMEN1MAPK1ALDH1A1LMNA | |
| SCHEMBL2049124 | 0.74 | ALDH1A1 (0.39) | KMT2AMEN1MAPK1ALDH1A1LMNA | |
| SCHEMBL2049125 | 0.74 | ALDH1A1 (0.39) | KMT2AMEN1MAPK1ALDH1A1LMNA | |
| SCHEMBL11634041 | 0.73 | MAPK1 (0.48) | KMT2AMEN1MAPK1ALDH1A1RAB9A | |
| SCHEMBL14572071 | 0.73 | ALDH1A1 (0.54) | KMT2AMEN1MAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2046021 | 0.72 | ALDH1A1 (0.32) | KMT2AMEN1MAPK1ALDH1A1LMNA | |
| SCHEMBL2045395 | 0.72 | RAB9A (0.38) | KMT2AMEN1MAPK1ALDH1A1LMNA | |
| SCHEMBL11638240 | 0.72 | MEN1 (0.48) | KMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL11632039 | 0.70 | RAB9A (0.63) | KMT2AMEN1MAPK1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771331-B2 | Methods of identifying neuroprotective compounds for retinal ganglion cells | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771331-B2 | Methods of identifying neuroprotective compounds for retinal ganglion cells | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771331-B2 | Methods of identifying neuroprotective compounds for retinal ganglion cells | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20090215765-A1 | Neuroprotective compounds for treating optic neuropathies | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215765-A1 | Neuroprotective compounds for treating optic neuropathies | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215765-A1 | Neuroprotective compounds for treating optic neuropathies | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-08-27 | — | — | US | disclosed |
| WO-2006116301-A1 | NEUROPROTECTIVE COMPOUNDS FOR TREATING OPTIC NEUROPATHIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215765-A1 | Neuroprotective compounds for treating optic neuropathies | NLN, GAP43, AIFM1 | KMT2A 4656/4885MEN1 3432/4885MAPK1 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.